

REMARKS

Claims 1-20 are subject to restriction.

Response to Restriction Requirement

The Examiner has required restriction to one of the following inventions:

- I. Claims 1-7 drawn to products of Formula II.
- II. Claims 1-7 drawn to products of Formula I not covered by Group I.
- III. Claims 8-20 drawn to the process of using products of Group I.
- IV. Claims 8-20 drawn to the process of using products of Group II.

Applicants hereby elect to prosecute the invention of Group I without traverse.

Response to Species Selection Requirement

The Examiner has required election of a single disclosed species "in case no generic claim is found to be allowable." Applicants hereby elect 5-Bromo-6-amino-3-(morpholin-4-ylsulfonyl)-1*H*-indole-2-carboxamide as a representative species.

Claims 2-7 remain pending in the instant application after the foregoing amendments. Applicants note that Claims 1 and 8-20 have been withdrawn without prejudice to filing a continuation or a divisional application directed to such inventions.

If a telephonic communication with the Applicants' representative will advance the prosecution of the instant application, please telephone the representative indicated below. Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this response to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By: 

Matthew A. Leff

Registration No. 50,149

Attorney for Applicants

MERCK & CO., INC.

P.O. Box 2000 - RY 60-30

Rahway, New Jersey 07065-0907

Telephone No. (732) 594-1404

Date: September 10, 2007